Onivyde
(asked on 16th March 2017) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when he expects a decision to be made on approval of the Onivyd drug for NHS use in the treatment of pancreatic cancer.
This question was answered on 24th March 2017
The National Institute for Health and Care Excellence currently expects to publish final guidance on the use of Onivyde (pegylated liposomal irinotecan) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy in April 2017.